DV
Dividend Vision

NGEN — NervGen Pharma Corp.

NervGen Pharma Corp. (NGEN)

Total return is 33.4% over the past 7.4 years, 168.3 points behind SPY at 201.7%. Its deepest 1-year drawdown was 73.4%.

NGEN is an equity stock with a 2019 inception date. The fund lacks essential dividend metrics including a distribution rate, expense ratio, and asset under management data, which limits assessment of its income-generation profile. The absence of distribution information and standardized fund characteristics suggests this may not be a traditional dividend-focused ETF structure.

NGEN key facts

Asset type
Stock
Asset class
Equity
Inception date
04/03/2019
Last close
$1.74
Market cap
$184,093,856
Average volume
562864.0
Beta
0.694
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.45